A marketing authorization application for etranacogene dezaparvovec is currently under review by the EMA.
The IND clearance comes after Legend terminated another clinical trial in T-cell lymphoma in July 2022.
Omidubicel’s BLA was originally accepted for priority review in August of this year.
Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.
Statistically significant improvements in cognitive development were only seen in the cohort of patients younger than 30 months.